Extracellular Vesicles Derived From Adult and Fetal Bone Marrow Mesenchymal Stromal Cells Differentially Promote
BMSCs
EV cargo
HSPC expansion
extracellular vesicles
hematopoietic niche
intercellular communication
transplantation
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
12
2020
accepted:
02
02
2021
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
16
3
2021
Statut:
epublish
Résumé
Recently, we and others have illustrated that extracellular vesicles (EVs) have the potential to support hematopoietic stem and progenitor cell (HSPC) expansion; however, the mechanism and processes responsible for the intercellular communication by EVs are still unknown. In the current study, we investigate whether primary human bone marrow derived mesenchymal stromal cells (BMSC) EVs isolated from two different origins, fetal (fEV) and adult (aEV) tissue, can increase the relative low number of HSPCs found in umbilical cord blood (UCB) and which EV-derived components are responsible for
Identifiants
pubmed: 33718342
doi: 10.3389/fbioe.2021.640419
pmc: PMC7947881
doi:
Types de publication
Journal Article
Langues
eng
Pagination
640419Informations de copyright
Copyright © 2021 Ghebes, Morhayim, Kleijer, Koroglu, Erkeland, Hoogenboezem, Bindels, van Alphen, van den Biggelaar, Nolte, van der Eerden, Braakman, Voermans and van de Peppel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood. 2017 Jun 22;129(25):3344-3351
pubmed: 28408459
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Stem Cells Transl Med. 2020 Oct;9(10):1153-1162
pubmed: 32619330
Front Immunol. 2016 Nov 09;7:470
pubmed: 27881982
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Genes Dev. 2014 Apr 15;28(8):858-74
pubmed: 24736844
Nat Rev Immunol. 2017 Sep;17(9):573-590
pubmed: 28604734
Bone Marrow Transplant. 2008 May;41(9):771-8
pubmed: 18209724
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Development. 2018 Jan 22;145(2):
pubmed: 29358215
Syst Synth Biol. 2015 Jun;9(1-2):1-10
pubmed: 25972984
Lancet Haematol. 2020 Feb;7(2):e134-e145
pubmed: 31704264
Cells. 2019 Dec 11;8(12):
pubmed: 31835680
Blood. 2015 Apr 23;125(17):2621-9
pubmed: 25762174
N Engl J Med. 2006 Apr 27;354(17):1813-26
pubmed: 16641398
Stem Cell Reports. 2018 Jul 10;11(1):274-287
pubmed: 29937145
Stem Cells Dev. 2018 Nov 1;27(21):1494-1506
pubmed: 30084753
Sci Rep. 2019 Mar 18;9(1):4785
pubmed: 30886165
Genome Biol. 2014;15(12):550
pubmed: 25516281
Science. 2014 Sep 19;345(6203):1509-12
pubmed: 25237102
J Clin Invest. 2014 Jul;124(7):3121-8
pubmed: 24911148
Cell Stem Cell. 2016 Jan 7;18(1):144-55
pubmed: 26669897
Stem Cells Dev. 2016 Jun 15;25(12):934-47
pubmed: 27154244
N Engl J Med. 2012 Dec 13;367(24):2305-15
pubmed: 23234514
Nat Methods. 2014 Mar;11(3):319-24
pubmed: 24487582
Sci Rep. 2016 Sep 02;6:32034
pubmed: 27585950
Nat Med. 2010 Feb;16(2):232-6
pubmed: 20081862
Cell Rep. 2018 Oct 30;25(5):1346-1358
pubmed: 30380423
Theranostics. 2018 Jan 1;8(4):906-920
pubmed: 29463990
Bone Marrow Transplant. 2020 Jan;55(1):48-61
pubmed: 31089283
Blood Rev. 2009 Sep;23(5):199-204
pubmed: 19282073
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Oncotarget. 2016 Feb 9;7(6):6676-92
pubmed: 26760763
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14229-34
pubmed: 20616003
Biol Blood Marrow Transplant. 2018 Jul;24(7):1463-1470
pubmed: 29477778
N Engl J Med. 2014 Jul 24;371(4):339-48
pubmed: 25054717
FASEB J. 2020 Apr;34(4):5435-5452
pubmed: 32086861
J Mol Biol. 2016 Feb 22;428(4):688-692
pubmed: 26434508
Nucleic Acids Res. 2020 Jan 8;48(D1):D142-D147
pubmed: 31691816
Stem Cells Int. 2016;2016:6493241
pubmed: 27042183
Blood. 2013 Apr 11;121(15):2875-81
pubmed: 23390194
Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):165-70
pubmed: 18162238